From artificial intelligence to tailor-made medicines, Scripps Research scientists weigh in on how the future of science and medicine will reshape health, disease and our everyday lives.
How science and innovation can mitigate future pandemics
Irene Khalek is on a quest to design a universal antivenom and protect people around the world from the deadliest snakebites.
Katja Lamia shares how our internal circadian clocks dictate the rhythm of our lives.
Learn about encouraging preliminary data from nine subjects in a first-in-human clinical trial studying the first switchable CAR-T cell product for patients with B-cell malignancies.
AbbVie (NYSE: ABBV) and Scripps Research announced earlier this year a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.
Calibr presented preliminary data on the development of a novel switchable CAR-T cell platform for patients with relapsed/refractory lymphoma and leukemia.
An experimental treatment called 3K3A-APC, which was co-developed at Scripps Research and has shown promise against amyotrophic lateral sclerosis (ALS) in preclinical studies, is now being tested in patients with the disease.
Scripps Research advances scientific understanding, educates the scientists of tomorrow and impacts human health across the globe. We are science changing life.